Home Metabolism -Neuronal Signaling FAAH

FAAH Inhibitors

FAAH Products

  • All (12)
  • FAAH Inhibitors (11)
  • New FAAH Products
Cat.No. Product Name Information Product Use Citations Product Validations
S2631 URB597 URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.
Exp Cell Res, 2025, 449(2):114602
Int J Mol Sci, 2024, 25(22)12044
IRIS, 2023,
S2377 Biochanin A Biochanin A (4-Methylgenistein), an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM.
Mol Neurobiol, 2022, 10.1007/s12035-021-02674-6
Front Oncol, 2021, 11:652008
J Med Virol, 2019, 91(8):1440-1447
S2666 PF-3845 PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2.
Elife, 2020, 9;9:e55211
Front Pharmacol, 2020, 11:266
Sci Rep, 2020, 10(1):15556
S0497 JNJ-42165279 JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively.
Cell Death Differ, 2022, 10.1038/s41418-022-01054-4
S2421 PF-04457845 PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. This compound covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily.
Front Chem, 2018, 6:441
F2107 FAAH1 Antibody [J10G16]
S5329 FAAH-IN-2 FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH).
S6609 JZL195 JZL195 is a potent inhibitor of both FAAH and MAGL with IC50s of 2 and 4 nM respectively.
S3586 URB937 URB937 is an orally active and peripherally restricted FAAH inhibitor with IC50 of 26.8 nM and increases anandamide levels.
S2828 JNJ-1661010 JNJ-1661010 (Takeda-25) is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2.
S5932 BIA 10-2474 BIA 10-2474 is a novel fatty acid amide hydrolase (FAAH) inhibitor, with a potent inhibitory effect upon FAAH and prolonged action in vivo.
S8052 LY-2183240 LY-2183240 is a potent, covalent inhibitor of the EC-degrading enzyme fatty acid amide hydrolase (FAAH). This compound disrupts the cellular uptake of the lipid endocannabinoid (EC) anandamide and promote analgesia in vivo. It is also an inhibitor of monoacylgylcerol lipase (MGL).
S2631 URB597 URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.
Exp Cell Res, 2025, 449(2):114602
Int J Mol Sci, 2024, 25(22)12044
IRIS, 2023,
S2377 Biochanin A Biochanin A (4-Methylgenistein), an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM.
Mol Neurobiol, 2022, 10.1007/s12035-021-02674-6
Front Oncol, 2021, 11:652008
J Med Virol, 2019, 91(8):1440-1447
S2666 PF-3845 PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2.
Elife, 2020, 9;9:e55211
Front Pharmacol, 2020, 11:266
Sci Rep, 2020, 10(1):15556
S0497 JNJ-42165279 JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively.
Cell Death Differ, 2022, 10.1038/s41418-022-01054-4
S2421 PF-04457845 PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. This compound covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily.
Front Chem, 2018, 6:441
S5329 FAAH-IN-2 FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH).
S6609 JZL195 JZL195 is a potent inhibitor of both FAAH and MAGL with IC50s of 2 and 4 nM respectively.
S3586 URB937 URB937 is an orally active and peripherally restricted FAAH inhibitor with IC50 of 26.8 nM and increases anandamide levels.
S2828 JNJ-1661010 JNJ-1661010 (Takeda-25) is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2.
S5932 BIA 10-2474 BIA 10-2474 is a novel fatty acid amide hydrolase (FAAH) inhibitor, with a potent inhibitory effect upon FAAH and prolonged action in vivo.
S8052 LY-2183240 LY-2183240 is a potent, covalent inhibitor of the EC-degrading enzyme fatty acid amide hydrolase (FAAH). This compound disrupts the cellular uptake of the lipid endocannabinoid (EC) anandamide and promote analgesia in vivo. It is also an inhibitor of monoacylgylcerol lipase (MGL).

Signaling Pathway Map